TY - JOUR
T1 - Heparan N-sulfatase gene
T2 - Two novel mutations and transient expression of 15 defects
AU - Esposito, Sabrina
AU - Balzano, Nicola
AU - Daniele, Aurora
AU - Villani, Guglielmo R D
AU - Perkins, Kelly
AU - Weber, Birgit
AU - Hopwood, John J.
AU - Di Natale, Paola
N1 - Funding Information:
This work was supported in part by Telethon-Italy (Grant E.812) and in part by Contributo Cofinanziamento Programmi di Ricerca di Interesse Nazionale Es.Fin. 1997 and the NH and MRC in Australia. Several MPS IIIA fibroblasts, obtained from Gaslini Institute, Genova, Italy, were from ‘Cell lines and DNA Bank from patients affected by genetic diseases’, partially supported by Telethon-Italy (Grant C.32).
PY - 2000/4/15
Y1 - 2000/4/15
N2 - Sanfilippo syndrome type A or mucopolysaccharidosis IIIA (MPS IIIA) results from the deficiency of the enzyme heparan N-sulfatase (NS, EC 3.10.1.1), required for the degradation of heparan sulfate. Molecular defects of 24 Italian MPS IIIA patients were recently reported by our group. We report here two novel mutations: 1040insT and Q365X and the expression studies on 15 of the identified defects. Transient expression of COS cells by cDNA mutagenized to correspond to heparan N-sulfatase mutations Y40N, A44T, 166delG, G122R, P128L, L146P, R150Q, D179N, R182C, R206P, P227R, 1040insT, 1093insG, E369K, R377C did not yield active enzyme, demonstrating the deleterious nature of the mutations. Western blot analysis and metabolic labeling experiments revealed, for cells transfected with wild-type enzyme, a precursor 62-kDa form and a mature 56-kDa form. Western blot resulted, for 11 mutations, in the presence of both forms, indicating a normal maturation of the mutant enzyme. Western blot, metabolic labeling and immunofluorescence experiments suggested, for mutations 166delG, L146P, 1040insT and 1093insG, an increased degradation of the mutant enzymes. (C) 2000 Published by Elsevier Science B.V.
AB - Sanfilippo syndrome type A or mucopolysaccharidosis IIIA (MPS IIIA) results from the deficiency of the enzyme heparan N-sulfatase (NS, EC 3.10.1.1), required for the degradation of heparan sulfate. Molecular defects of 24 Italian MPS IIIA patients were recently reported by our group. We report here two novel mutations: 1040insT and Q365X and the expression studies on 15 of the identified defects. Transient expression of COS cells by cDNA mutagenized to correspond to heparan N-sulfatase mutations Y40N, A44T, 166delG, G122R, P128L, L146P, R150Q, D179N, R182C, R206P, P227R, 1040insT, 1093insG, E369K, R377C did not yield active enzyme, demonstrating the deleterious nature of the mutations. Western blot analysis and metabolic labeling experiments revealed, for cells transfected with wild-type enzyme, a precursor 62-kDa form and a mature 56-kDa form. Western blot resulted, for 11 mutations, in the presence of both forms, indicating a normal maturation of the mutant enzyme. Western blot, metabolic labeling and immunofluorescence experiments suggested, for mutations 166delG, L146P, 1040insT and 1093insG, an increased degradation of the mutant enzymes. (C) 2000 Published by Elsevier Science B.V.
KW - Heparan N-sulfatase
KW - Mucopolysaccharidosis IIIA
KW - Mutation analysis
KW - Sanfilippo syndrome type A
KW - Transient expression
UR - https://www.scopus.com/pages/publications/0034656211
U2 - 10.1016/S0925-4439(99)00118-0
DO - 10.1016/S0925-4439(99)00118-0
M3 - Article
C2 - 10727844
AN - SCOPUS:0034656211
SN - 0925-4439
VL - 1501
SP - 1
EP - 11
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 1
ER -